Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
AskMen.com	Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus.
The Motley Fool November 29, 2007 Brian Lawler	Another Chapter in Glaxo's Relenza Saga An FDA advisory panel suggested that the Relenza label should be strengthened to include the possibility of abnormal behavior and hallucinations in those who take it.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool November 30, 2006 Brian Lawler	Happy (Sniffle) Holidays (Cough) It's flu season again, and the market for influenza vaccines is hot. Pharma investors, take note.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
BusinessWeek February 9, 2004 Catherine Arnst	What You Need To Know About Avian Flu The current avian flu outbreak in Asia is the fifth since 1997 to infect humans. This has raised a red flag for infectious disease experts, who fear the strain could mutate and spark a devastating flu pandemic.
The Motley Fool April 19, 2006 John Bluis	Gilead's Got Cash Up to the Gills The pharmaceutical cashes in on bird-flu fears. The company's strong performance means that investors have to pay a slight premium for its shares.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
BusinessWeek October 31, 2005 Gene G. Marcial	Why Biocryst Has Wings Shares of the pharmaceutical are on fire, soaring from $4.39 a share in early April to $15 on Oct. 19.
BusinessWeek September 19, 2005 Catherine Arnst	A Hot Zone In The Heartland Little could be done to contain a deadly avian flu outbreak. Right now, the U.S. has no national pandemic preparedness plan, either for treating large numbers of patients or for dealing with the resulting economic and social disruptions.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
Chemistry World May 14, 2008 Simon Hadlington	Bird Flu's Drug Resistance Mapped UK scientists have shown exactly why a mutant version of the deadly bird flu virus H5N1 becomes resistant to the drug oseltamivir - marketed as Tamiflu.
Pharmaceutical Executive September 1, 2005 Patrick Clinton	From the Editor: It Never Changes (Until It Does) Change is bubbling around through the industry, its customers, and its regulators. Should pharmaceutical companies be doing the equivalent of taking two aspirin and calling in the morning or building an ark?
The Motley Fool December 2, 2010 Brian Orelli	An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
AskMen.com Jacob Franek	Avian Influenza 101 Here is everything you need to now about avian influenza so that you can better protect yourself.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool July 20, 2007 Andrew R. Vaino	BioCryst Is for the Birds Fears of bird flu resurrected a drug for this small pharma, and it has some other promising compounds in the pipeline. Based only on its pipeline size, BioCryst should be valued higher. But make no mistake: This is a risky stock.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
Searcher June 2006 Eva C. Perkins	Is the Price of Cheap Chicken Bird Flu? Information professionals are faced with a situation in which our skills are called upon to soothe the public with reassuring data about the avian flu.
AskMen.com Jacob Franek	Swine Flu Update With the fall flu season rapidly approaching, a swine flu update is warranted.
The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool October 28, 2009 Brian Orelli	Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
Chemistry World January 7, 2014 Angeli Mehta	Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
BusinessWeek November 28, 2005 Kerry Capell	High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
The Motley Fool July 28, 2005 Stephen D. Simpson	Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results.
The Motley Fool January 12, 2010 Brian Orelli	Swine Flu: The Side Dish That Couldn't Last More governments canceling vaccine-purchasing contracts. The sky is falling on swine-flu-vaccine makers.
Popular Mechanics July 31, 2007 John Galvin	Spanish Flu Pandemic: 1918 The influenza pandemic of 1918 killed an estimated 50 million people around the world -- 34 million more than died from the First World War in progress alongside it.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
Health June 19, 2009 Ginny Graves	How to Combat the Latest Supergerms While some germs may be outpacing our ability to kill them, we're not completely defenseless. In fact, there are plenty of things we can do to slow their spread.
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.